Scalper1 News
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno Therapeutics (JUNO) shares at 93 each — more than double Monday’s closing price — for $850 million. In exchange, Celgene gets the option to license Juno’s two leading chimeric antigen receptor (CAR) T cell Scalper1 News
Scalper1 News